Novel me-too classes Dihydroxypyrimidine-4-carboxamides Soon after promising clinical data regarding the progress of MK-0518 became available, a novel DKA-related class of IN inhibitory compounds (Figure 3, Additional file 1) was developed through screening of inhibitors of HCV polymerase, which demonstrates a high degree of structural similarity to IN [ 31]. Specifically, IN and HCV polymerase possess a similar active site amino acid geometry, and both utilize two magnesium ions in their catalysis. A class of dihydroxypyrimidine carboxamides was derived as HCV polymerase inhibitors from DKAs, and they were found to exhibit improved drug-like properties and correct Mg 2+ binding geometry. Most of these compounds were inactive against IN, but a substitution of the free carboxylic acid with a benzyl amide yielded compound 1, with nanomolar IN inhibitory activity in enzymatic assays. Compound 1 showed a decent pharmacokinetic profile, with a bioavailability of 15%, plasma clearance of 5 mL/min/kg, and a half-life of 3 hours. Further structure activity relationship (SAR) studies upon the amide moiety of 1 led to the identification of a superior para-fluorobenzyl substituent (compound 2). Compound 2 exhibited an IC 50 of 10 nM in the enzymatic assay, as well as an improved oral bioavailability in rats of 29%. However, both compounds 1 and 2 were inactive in cell-based assays, due to poor solubility, poor cell permeability, and significant plasma protein binding [ 31]. | Figure 3 The evolution of dihydroxypyrimidine-4-carboxamides. |
This group pushed on in their search for raltegravir me-too drugs with further SAR studies upon the above N-alkyl hydroxypyrimidinone lead compounds (Figure 3). As a benzyl amide substitution of a free carboxyl instilled nanomolar activity upon said compounds, a library of over 200 different amide modifications was synthesized and screened for inhibitory potency [ 57]. A 4-fluoro-substituted benzene was shown to be optimal for IN inhibition, with an IC 50 value in enzymatic assays of 10 nM. However, though compounds optimized in this fashion were active in the enzymatic assay, they lacked potency in cell based assays. The thiophene ring in the 2-position of the pyrimidine core was shown to have little effect upon the interaction of the compound with IN, and so this position was chosen for more dramatic changes influencing physiochemical properties of inhibitors. Introduction of a basic group to a 2-benzyl derivative resulted in increased cell permeability and inhibition of viral replication in the presence of fetal bovine serum (FBS) with a CIC 95 of 300 nM (compound 3). This compound showed an oral bioavailability of 59% and 93%, a half-life of 1.73 h and 6.78 h, and a plasma clearance of 14 mL/min/kg and 0.5 mL/min/kg in rats and dogs, respectively. However, weak activity in the presence of 50% NHS exposed the mobile nature of chosen 2-position substituents. In response the phenyl group at this position was removed and the NH methylated, to confer reduced lipophilicity (and reduced plasma protein binding) but maintain the presence of the mandatory amino group. Compound 4 was thus born, exhibiting a 95% human plasma protein binding and a 400 nM CIC 95 in the presence of 50% NHS. Pharmacokinetics of compound 4 included an oral bioavailability of 27% and 90%, a half-life of 0.43 h and 6.0 h, and a plasma clearance of 75 mL/min/kg and 2 mL/min/kg in rats and dogs, respectively. Separately, smaller acyclic amines were substituted into the 2 position and similarly assayed for activity [ 57]. It was found that a dimethylaminomethyl substituent separated by an sp 3-carbon spacer bestowed significant cell based potency, at a CIC 95 of 78 nM in 50% NHS (compound 5). In rats, dogs, and monkeys, compound 5 had a prolonged plasma half-life (2.1, 4.8, and 1.9 h, respectively), moderate to low clearance (16, 1.9, and 15 mL/min/kg, respectively) and moderate to excellent oral bioavailability (28%, 100%, and 61%, respectively) [ 57]. N-methylpyrimidones To improve cell-based potency and bioavailability of the above molecules, this group began to study the effect of methylation of their N-1 pyrimidine nitrogens (Figure 4, Additional file 1). The rationale for this decision was based upon their discovery that the amine contained in the ring must occupy the benzylic position with respect to the pyrimidine and that small alkyl groups are preferred on the nitrogen of the saturated heterocycle [ 57]. A methyl group was initially scanned on the pyrrolidine ring, and substitution on position 4 gave the best enzymatic activity. Substitution of the free hydroxyl group of a resulting trans-4-hydroxy pyrrolidine with a methoxy substituent produced potent activity (compound 6) in both in vitro (IC 50 = 180 nM) and cell-based assays (CIC 95 = 170 nM in 50% NHS) [ 58]. From here the group tested other substitutions, of which a fluorine (compound 7 – CIC 95 = 250 nM) or a difluoro derivative (compound 8 – CIC 95 = 170 nM) were well accepted. Activity was found to be further augmented by substituting a six-membered derivative in position 2 of the pyrimidine, and the morpholine derivative 9 and piperidine derivative 10 displayed slightly improved cell-based potencies (100 nM and 190 nM CIC 95 in 50% NHS, respectively). In terms of pharmacokinetics, the morpholine derivative 9 was the most ideal candidate for further testing, with bioavailabilities of 92%, 100%, and 53%; half-lives of 1.5 h, 10 h, and 1.4 h; and plasma clearance rates of 22 mL/min/kg, 3 mL/min/kg, and 14 mL/min/kg in rat, dog, and rhesus monkey, respectively [ 58]. | Figure 4 The evolution of N-methylpyrimidones. |
A further optimization study analyzed the enzymatic and pharmacokinetic implications of a different, tbutyl substitution at the C-2 position of the pyrimidine scaffold of the above compounds [Figure 4, [ 59]]. Further introduction of a benzylamide to the right side of the scaffold proved necessary for activity in serum conditions. Multiple derivatives were designed using the N-methyl pyrimidone scaffold, including a sulfone (compound 11) and an N-methyl amide (compound 12) that showed CIC 95s of 20 nM and 10 nM in 50% NHS, respectively. This encouraging data inspired further substitutions of the 2- N-methyl carboxamide, for optimization of pharmacokinetic behavior. An unsubstituted amide 13 exhibited a promising inhibitory profile (IC 50 = 20 nM in enzymatic assay, CIC 95 = 10 nM in 50% NHS), prompting multiple further substitutions of the N-methyl residue with an N-ethyl (compound 14) and an iN-propyl (compound 15). The pharmacokinetic profiles of 11, 12, and 13 were not optimal (Additional file 1), and none of these substitutions were beneficial in this respect. Bioavailability was 17%, 18%, and 23%; half-life was 1.8 h, 1.6 h, and 3.6 h; and plasma clearance was 37 mL/min/kg, 24 mL/min/kg, and 55 mL/min/kg in rat for 11, 12, and 13, respectively [ 59]. Dihydroxypyrido-pyrazine-1,6-diones Parallel to the above N-methylpyrimidone studies, the same group was working toward optimization and cyclic constraint of the dihydroxypyrimidine-4-carboxamide amide side chain, yielding a novel class of dihydroxypyridopyrazine-1,6-dione compounds [Figure 5, [ 60]]. Coplanarity of the amide carbonyl group in the constrained ring with respect to the dihydroxypyridinone core and a resulting limitation of flexibility of the 4-fluorobenzyl side chain (compound 16) were shown through molecular modeling to be essential for inhibitory activity. Compound 16 inhibited IN strand transfer in vitro at an IC 50 of 100 nM and HIV replication in cell culture at a CIC 95 of 310 nM, with little cytotoxicity. Limited pharmacokinetic data has been provided for this class of compounds, but compound 16 was shown to have a 69% oral bioavailability in rats, and plasma concentrations were maintained between 0.64 and 0.50 μM from the second to the twenty-fourth hour (Additional file 1). There was concern about the dihydroxypyrimidone core and its metabolites irreversibly associating with liver microsomal proteins, but only a non-significant level (<50 pmol equiv/mg/60 min) of interaction was observed [ 60]. | Figure 5 Dihydroxypyrido-pyrazine-1,6-dione representative example. |
Bicyclic pyrimidones Recently, the aforementioned importance of a β-amino substituent in the 2-position of the pyrimidine scaffold and the beneficial effect of the 1 N-methylation were exploited in a systematic constraint of the 1 N-methyl on the 1 N-methylpyrimidinone scaffold (Figure 6, Additional file 1). With unsubstituted benzylmethylamine derivatives showing nanomolar enzymatic inhibition profiles similar to those of derivatives with saturated ring side chains (though little inhibition of viral replication in cell culture), it was decided that the 2- β-nitrogen would be modified to optimize physiochemical properties of pyrimidone compounds [ 61]. For example, introduction of a sulfonamide (compound 17) resulted in a low shift in activity in serum conditions, suggesting an increased level of cell permeability. The ( R)-17 enantiomer displayed a 7 nM enzymatic IC 50 value, a 31 nM CIC 95 in 50% NHS (two-fold more potent than its ( S)-17 enantiomer contemporary), and acceptable pharmacokinetics including a 17% bioavailability and 55 mL/min/kg plasma clearance in rat. Sulfonamide derivatives showed similarly decent profiles (compound 18 = 12 nM IC 50 against strand transfer, 86 nM CIC 95 in cells in 50% NHS, and a 47% bioavailability and 48 mL/min/kg plasma clearance in rats). However, an even more significant improvement in potency occurred upon changing the sulfonamide moiety to a tetrasubstituted sulfamide (compound 19). The ( R)-19 enantiomer inhibited IN with an IC 50 value and a CIC 95 value of 7 nM and 44 nM, respectively, but pharmacokinetics (9% bioavailability in rhesus monkey) were inadequate. Introduction of a more polar N-methylpiperazine (compound 20), however, produced a compound whose (S)-20 enantiomer inhibited IN at a CIC 95 of 6 nM in cell culture in the presence of 50% NHS. This compound was much more stable toward glucuronidation than its sulfamide counterpart, but low bioavailability and high plasma clearance in rats and dogs neutralized its promise. It was hence necessary to make use of other nitrogen functionalizations in order to optimize these pharmacological properties. The substitution of ketoamides and enlarged rings (compounds 21 and 22, respectively) resulted in potent inhibition of IN in cell based assays and much improved pharmacokinetics. The ( S)-enantiomers of both compounds achieved CIC 95s of 43 nM and 13 nM in cell culture, respectively, as well as moderate pharmacologic properties in rats, dogs, and (compound ( S)-22 only) monkeys [ 61]. | Figure 6 The evolution of bicyclic pyrimidones. |
Pyrrolloquinolones A different group has recently built upon their prior optimization of the clinically efficacious L870,810 [ 62, 63] by varying C5 substituents within their compounds' tricyclic scaffolds (Figure 7, Additional file 1). They originally developed the tricyclic scaffold to provide a pre-organized, energetic improvement to L870,810's unfavorable energy consumption upon rotational conversion from free state to bound state, leading to a more soluble and potent compound 23 [ 62]. In their recent work, C5-amino derivatives were prepared and assayed for improvement in strand transfer inhibitory potency and pharmacokinetics, due to their projected higher stability against hydrolysis than analogous carbamates or sulfamates [ 64]. The most promising leads turned out to be a C5 sulfonamide (compound 24), a C5 sulfonylurea (compound 25), and a C5 sultam (compound 26). Compounds 24 and 25 retained potency in the presence of serum albumin and α-1 acidic glycoproteins, while 26 was negatively affected. Though the sultam 26 showed a lower IC 50 than the sulfonamide 24 and sulfonylurea 25 in enzymatic assays (13 nM as opposed to 28 nM and 62 nM, respectively), it lacked potency in cell culture in 50% NHS (EC 50 49 nM as opposed to 11.4 nM and 8.4 nM, respectively). It is important to note that raltegravir showed an EC 50 value of 16 nM in cell culture in the presence of 50% NHS. Compound 26 was additionally lacking in bioavailability in both rat (4%) and dog (8%). However, compounds 24 and 25 showed slightly more promising profiles, with bioavailabilities of 15%/13% and 45%/16% and half-lives of 1.1 h/0.9 h and 4.9 h/4.5 h in rat and dog, respectively [ 64]. This study exemplified the importance of rigidifying inhibitor pharmacophores in terms of conferring favorable potency and pharmacokinetic properties. | Figure 7 The evolution of pyrrolloquinolones. |
Validation of resistance profiles of me-too raltegravir analogues Though there is minor variation in the in vitro activity of the above me-too IN inhibitors, their structures, mechanisms of action, and pharmacokinetics are highly similar. We believe that the development of me-too compounds may yield a relatively low amount of clinical success due to their similarities, and also due to the fact that nearly identical resistance profiles will be evoked by their application. However, we would like to note that it is definitely possible for a raltegravir me-too analog to evolve into a second-generation IN inhibitor. To further elucidate our viewpoint, we utilized the molecular docking program GOLD version 3.2 to conduct a docking study, using both the X-ray determined structure of 1BL3 IN complexed with an Mg 2+ ion, and a collection of significant, above-described me-too compounds (Figure 8); for a detailed procedure, see [ 65]. We propose that residues essential to the compounds' interaction with IN will obviously be prime candidates for resistance mutation. Furthermore, we hypothesize that the test of time will show that all of these me-too inhibitors will probably exhibit highly similar resistance profiles. As raltegravir has undergone extensive resistance profiling since the inception of its clinical employment (Table 1), we first compared our predicted interaction residues (Figure 8) to these experimental profiles, as a validation of the reliability of our technique. We found that five of our predicted interaction residues (T66, E92, Y143, Q148, and N155) have been already observed to confer a range of anywhere from 5- to 35-fold resistances to raltegravir inhibition of viral replication, respectively [ 66- 69]. We also saw that raltegravir makes direct interactions with the three residues encompassing the IN catalytic DDE motif (D64, D116, and E152), including a hydrogen bond with the glutamate. With this technique corroboration in hand, we decided to similarly predict the interaction residues of raltegravir's progenitors and a few me-too analogues, in order to provide evidence for our assertion that these compounds will ultimately experience a low probability of success in viral eradication, due to their generation of identical resistance profiles. As S-1360 was the first clinical IN inhibitor candidate, we thought it would be interesting to evaluate the similarity between its predicted interaction profile with 1BL3 (Figure 8) and that of raltegravir. We found that an identical interaction occurs between the two drugs and IN (D64, T66, D116, Y143, Q148, E152, and N155), but predicted an additional interaction of raltegravir with E92. This observation has been verified in clinical experimental resistance profiling, as mutation of E92 has not been observed for S-1360, but the E92Q mutation has conferred up to a 7-fold viral resistance to raltegravir [ 25, 26, 70]. We next observed the interaction profile of 1BL3 with L870,810 (Figure 8), as this is the naphthyridine carboxamide compound that directly led to the development of pyrimidinone carboxamides. We found that L870,810 and raltegravir similarly interacted with D64, T66, D116, Q148, E152, and N155. However, we saw here that only raltegravir interacted with E92. Though this residue has been observed to be mutated to a glutamine in response to L870,810 treatment, the mutation has conferred at most only a 2-fold resistance to the drug, while the same mutation confers up to a 7-fold resistance to raltegravir (Table 1) [ 29, 71]. The fact that we did not observe a significant interaction between L870,810 and E92 in our docking study further confirms the relatively decreased importance of this residue in viral resistance to the compound. Along the same lines, we did see an interaction of L870,810 with V151, an interaction that was not present in our docking of raltegravir. In clinical experimental resistance profiling, the V151I mutation has been observed to confer up to an 18-fold resistance to L870,810, while the same mutation had a negligible effect on viral resistance to raltegravir (Table 1) [ 29, 71]. The highly homologous naphthyridine carboxamide candidate, L870,812, has shown an interaction profile virtually identical to that of L870,810 in our docking study, and experimental resistances obtained in clinical observation have been identical as well [ 29, 71]. As elvitegravir (GS-9137) and GSK-364735 have already been shown to exhibit near identical resistance profiles to raltegravir (Table 1) [ 67, 71- 73], we next used our docking technique to attempt to effectively predict these interactions (Figure 8). For GSK-364735, we were able to predict the interaction with IN residues Y143 and Q148, as well as the three members of the DDE motif. We then predicted that, similar to raltegravir, elvitegravir interacts with T66, E92, Y143, Q148, and the D116 and E152 of the DDE motif. We also saw that elvitegravir interacts with G140, and the G140S mutation has been shown to be associated with a 4-fold viral resistance to the drug, while the same mutation confers only a 1.6-fold resistance to raltegravir (Table 1). Again, the fact that we did not observe a significant interaction between raltegravir and G140 in our docking study further confirms the relatively decreased importance of this residue in viral resistance to raltegravir, but rather its nature of compensation for more meaningful mutations, such as Q148H. | Figure 8 Docking poses of selected HIV-1 integrase inhibitors upon the 1BL3 IN crystal structure. A, MK-0518; B, S-1360; C, L870,810; D, GSK-364735; E, GS-9137; F, compound 2; G, compound 11; H, compound 16; I, compound 17; J, compound 26. |
| Table 1 Effect of single mutations on IN sensitivity to clinically tested inhibitors. |
|
References Klimas N, Koneru AO, Fletcher MA. Overview of HIV. Psychosom Med. 1984;70:523–530. [PubMed]Hammer SM, Eron JJ, Jr, Reiss P, Schooley RT, Thompson MA, Walmsley S, Cahn P, Fischl MA, Gatell JM, Hirsch MS, Jacobsen DM, Montaner JS, Richman DD, Yeni PG, Volberding PA. Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society USA panel. JAMA. 2008;300:555–570. [PubMed]Gazzard B, Anderson J, Babiker A, Churchill D, Collins S, Fisher M, Johnson M, Khoo S, Leen C, Loveday C, Moyle G, Nelson M, Peter B, Phillips A, Pillay D, Wilkins E, Williams I, Youle M. British HIV Association guidelines for the treatment of HIV-1-infected adults with antiretroviral therapy 2008: pre-press version. HIV Med. 2003. pp. 1–41. [PubMed]Gulick RM, Mellors JW, Havlir D, Eron JJ, Gonzalez C, McMahon D, Richman DD, Valentine FT, Jonas L, Meibohm A, Emini EA, Chodakewitz JA. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med. 1997;337:734–739. [PubMed]Palella FJ, Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, Aschman DJ, Holmberg SD. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med. 1998;338:853–860. [PubMed]Gulick RM, Meibohm A, Havlir D, Eron JJ, Mosley A, Chodakewitz JA, Isaacs R, Gonzalez C, McMahon D, Richman DD, Robertson M, Mellors JW. Six-year follow-up of HIV-1-infected adults in a clinical trial of antiretroviral therapy with indinavir, zidovudine, and lamivudine. AIDS. 2003;17:2345–2349. [PubMed]Stebbing J, Bower M, Mandalia S, Nelson M, Gazzard B. Highly active anti-retroviral therapy (HAART)-induced maintenance of adaptive but not innate immune parameters is associated with protection from HIV-induced mortality. Clin Exp Immunol. 2006;145:271–276. [PubMed]Chun TW, Stuyver L, Mizell SB, Ehler LA, Mican JAM, Baseler M, Lloyd AL, Nowak MA, Fauci AS. Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proc Nat Acad Sci USA. 1997;94:13193–13197. [PubMed]Chun TW, Fauci AS. Latent reservoirs of HIV: obstacles to the eradication of virus. Proc Natl Acad Sci USA. 1999;96:10958–10961. [PubMed]Potter SJ, Lemey P, Achaz G, Chew CB, Vandamme AM, Dwyer DE, Saksena NK. HIV-1 compartmentalization in diverse leukocyte populations during antiretroviral therapy. J Leukoc Biol. 2004;76:562–570. [PubMed]Potter SJ, Lemey P, Dyer WB, Sullivan JS, Chew CB, Vandamme AM, Dwyer DE, Saksena NK. Genetic analyses reveal structured HIV-1 populations in serially sampled T lymphocytes of patients receiving HAART. Virology. 2006;348:35–46. [PubMed]Dayam R, Al-Mawsawi LQ, Neamati N. HIV-1 integrase inhibitors: an emerging clinical reality. Drugs R D 2007. 2007;8:155–168. Delelis O, Carayon K, Saib A, Deprez E, Mouscadet JF. Integrase and integration: biochemical activities of HIV-1 integrase. Retrovirology. 2008;5:114. [PubMed]Asante-Appiah E, Skalka AM. HIV-1 integrase: structural organization, conformational changes, and catalysis. Adv Virus Res. 1999;52:351–369. [PubMed]Brown PO. Integration. In: Coffin JM, Hughes SH, Varmus HE, editor. Retroviruses. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY; 1997. pp. 161–203. Hazuda DJ, Felock P, Witmer M, Wolfe A, Stillmock K, Grobler JA, Espeseth A, Gabryelski L, Schleif W, Blau C, Miller MD. Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells. Science. 2000;287:646–650. [PubMed]Espeseth AS, Felock P, Wolfe A, Witmer M, Grobler J, Anthony N, Egbertson M, Melamed JY, Young S, Hamill T, Cole JL, Hazuda DJ. HIV-1 integrase inhibitors that compete with the target DNA substrate define a unique strand transfer conformation for integrase. Proc Natl Acad Sci USA. 2000;97:11244–11249. [PubMed]Shionogi & Co. Ltd, W09950245. 1999. Marchand C, Zhang X, Pais GC, Cowansage K, Neamati N, Burke TR, Jr, Pommier Y. Structural determinants for HIV-integrase inhibition by β-diketo acids. J Biol Chem. 2002;277:12596–603. [PubMed]Goldgur Y, Craigie R, Cohen GH, Fujiwara T, Yoshinaga T, Fujishita T, Sugimoto H, Endo T, Murai H, Davies DR. Structure of the HIV-1 integrase catalytic domain complexed with an inhibitor: a platform for antiviral drug design. Proc Natl Acad Sci USA. 1999;96:13040–3. [PubMed]Shionogi & Co. Ltd, WO0039086. 2000. Billich A. S-1360 Shionogi-GlaxoSmithKline. Curr Opin Investig Drugs. 2003;4:206–9. [PubMed]Yoshinaga T, Sato A, Fujishita T, Fujiwara T. S-1360: In vitro activity of a new HIV-1 integrase inhibitor in clinical development. 9th Conference on Retroviruses and Opportunistic Infections Seattle, USA Feb 24th–28th, 2002. Rosemond MJ, St John-Williams L, Yamaguchi T, Fujishita T, Walsh JS. Enzymology of a carbonyl reduction clearance pathway for the HIV integrase inhibitor, S-1360: role of human liver cytosolic aldoketo reductases. Chem Biol Interact. 2004;147:129–39. [PubMed]Zhuang L, Wai JS, Embrey MW, Fisher TE, Egbertson MS, Payne LS, Guare JP, Jr, Vacca JP, Hazuda DJ, Felock PJ, Wolfe AL, Stillmock KA, Witmer WV, Moyer G, Schleif WA, Gabryelski LJ, Leonard YM, Lynch JJ, Jr, Michelson SR, Young SD. Design and synthesis of 8-hydroxy-[1,6]naphthyridines as novel inhibitors of HIV-1 integrase in vitro and in infected cells. J Med Chem. 2003;46:453–6. [PubMed]Hazuda DJ, Anthony NJ, Gomez RP, Jolly Sm, Wai JS, Zhuang L, Fisher TE, Embrey M, Guare JP, Jr, Egbertson MS, Vacca JP, Huff JR, Felock PJ, Witmer MV, Stillmock KA, Danovich R, Grobler J, Miller MD, Espeseth AS, Jin L, Chen IW, Lin JH, Kassahun K, Ellis JD, Wong BK, Xu W, Pearson PG, Schleif WA, Cortese R, Emini E, Summa V, Holloway MK, Young SD. A naphthyridine carboxamide provides evidence for discordant resistance between mechanistically identical inhibitors of HIV-1 integrase. Proc Natl Acad Sci USA. 2004;101:11233–8. [PubMed]Little S, Drusano G, Schooley R. Antiviral effect of L-000870810, a novel HIV-1 integrase inhibitor, in HIV-1 infected patients. 12th Conference on Retroviruses and Opportunistic Infections Feb 22–25, 2005 Boston, MA. Abstract 161. Summa V, Petrocchi A, Matassa VG, Gardelli C, Muraglia E, Rowley M, Paz OG, Laufer R, Monteagudo E, Pace P. 4,5-Dihydroxypyrimidine carboxamides and N-Alkyl-5-hydroxypyrimidinone carboxamides are potent, selective HIV integrase inhibitors with good pharmacokinetic profiles in preclinical species. J Med Chem. 2006;49:6646–9. [PubMed]Low A, Mohri H, Markowitz M. Frequency of naturally occurring polymorphisms associated with resistance to integrase inhibitors in a recently infected cohort. 14th Conference on Retroviruses and Opportunistic Infections Feb 25–28, 2007 Los Angeles, CA. Miller M, Witmer M, Stillmock K, Felock P, Ecto L, Flynn J, Schleif W, Dornadula G, Danovich R, Hazuda D. Biochemical and antiviral activity of MK-0518, a potent HIV integrase inhibitor. XVI International AIDS Conference August 13–18, 2006 Toronto, Canada. Gilbert J, Henske P, Singh A. Rebuilding big pharma's buisiness model. In Vivo. 2003;21:73–82. Grabowski H, Vernon J, DiMasi JA. Returns on research and development for 1990s new drug introductions. Pharmacoeconomics. 2002;20:11–29. [PubMed]Lee TH. "Me-too" products – friend or foe? (perspective). N Engl J Med. 2004;350:211–2. [PubMed]Frothingham R, Relman AS. "Me-too" products – friend or foe? (correspondence). N Engl J Med. 2004;350:2100–1. [PubMed]Austin PC, Mamdani MM, Jurlink DN. How many me-too drugs are enough: the case of physician preferences for specific statins. Ann Pharmacother. 2006;40:1047–51. [PubMed]Lind T, Rydberg L, Kyleback A, Jonsson A, Andersson T, Hasselgren G, Holmberg J, Rohs K. Esomeprazole provides improved acid control vs. omeprazole in patients with symptoms of gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 2000;14:861–7. [PubMed]Weiss RB. The anthracyclines: will we ever find a better doxorubicin? Semin Oncol. 1992;19:670–86. [PubMed]Vanderhoff BT, Ruppel HM, Amsterdam PB. Carvedilol: the new role of beta blockers in congestive heart failure. Am Fam Physician. 1998;58:1627–34. [PubMed]Schmid EF, Smith DA. Keynote review: is declining innovation in the pharmaceutical industry a myth? DDT. 2005;10:1031–9. [PubMed]Al-Mawsawi LQ, Al-Safi RI, Neamati N. Anti-infectivces: clinical progress of HIV-1 integrase inhibitors. Exp Opin Emerg Drugs. 2008;13:213–25. Cooper DA, Steigbigel RT, Gatell JM, Rockstroh JK, Katlama C, Yeni P, Lazzarin A, Clotet B, Kumar PN, Eron JE, Schechter M, Markowitz M, Loutfy MR, Lennox JL, Zhao J, Chen J, Ryan DM, Rhodes RR, Killar JA, Gilde LR, Strohmaier KM, Meibohm AR, Miller MD, Hazuda DJ, Nesly ML, DiNubile MJ, Isaacs RD, tippler H, Nguyen BY. Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection. N Engl J Med. 2008;359:355–65. [PubMed]Delelis O, Malet I, Na L, Tchertanov L, Calvez V, Marcelin AG, Subra F, Deprez E, Mouscadet JF. The G140S mutation in HIV integrases from raltegravir-resistant patients rescues catalytic defect due to the resistance Q148H mutation. Nucleic Acids Res. 2009 [PubMed]King NM, Pravu-Jeyabalan M, Nalivaika EA, Wigerinck P, de Bethune MP, Schiffer CA. Structural and thermodynamic basis for the binding of TMC114, a next-generation human immunodeficiency virus type 1 protease inhibitor. J Virol. 2004;78:12012–21. [PubMed]Koh Y, Nakata H, Maeda K, Ogata H, Bilcer G, Devasamudram T, Kincaid JF, Boross P, Wang YF, Tie Y, Volarath P, gaddis L, Harrison RW, Weber IT, Ghosh AK, Mitsuya H. Novel bis-tetrahydrofuranylurethane-containing nonpeptidic protease inhibitor (PI) UIC-94017 (TMC114) with potent activity against multi-PI-resistant human immunodeficiency virus in vitro. Antimicrob Agents Chemother. 2003;47:3121–9. Sato M, Motomura T, Aramaki H, Matsuda T, Yamashita M, Ito Y, Kawakami H, Matsuzaki Y, Watanabe W, Yamataka K, Ikeda S, Kodama E, Matsuoka M, Shinkai H. Novel HIV-1 integrase inhibitors derived from quinolone antibiotics. J Med Chem. 2006;49:1506–8. [PubMed]Pais GC, Zhang X, Marchand C, Neamati N, Cowansage K, Svarovskaia ES, Pathak VK, Tang Y, Nicklaus M, Pommier Y, Burke TR., Jr Structure activity of 3-aryl-1,3-diketo-containing compounds as HIV-1 integrase inhibitors. J Med Chem. 2002;45:3184–94. [PubMed]Vacca J, Wai J, Fisher T, et al. Discovery of MK-2048: subtle changes confer unique resistance properties to a series of tricyclic hydroxypyrrole integrase strand transfer inhibitors. 4th International AIDS Society (IAS) Conference Jul 22 – 25, 2007 Sydney, Australia. Wai J, Fisher T, Embrey M, et al. Next generation of inhibitors of HIV-1 integrase strand transfer inhibitor: structural diversity and resistance profiles. 14th Conference on Retroviruses and Opportunistic Infections Feb 25 – 28, 2007 Los Angeles, CA. Kearney B, Mathias A, Zhong L. Pharmacokinetics/pharmacodynamics of GS-9137 an HIV integrase inhibitor in treatment-naïve and experienced patients [abstract]. International Workshop on Clinical Pharmacology of HIV Therapy Lisbon. 2006. Shimura K, Kodama E, Sakagami Y, Matsuzaki Y, Watanabe W, Yamataka K, Watanabe Y, Ohata Y, Doi S, Sato M, Kano M, Ikeda S, Matsuoka M. Broad anti-retroviral activity and resistance profile of a novel human immunodeficiency virus integrase inhibitor, elvitegravir (JTK-303/GS-9137). J Virol. 2007;82:764–74. [PubMed]Garvey EP, Johns BA, Gartland MJ, Foster SA, Miller WH, Ferris RG, Hazen RJ, Underwood MR, Boros EE, Thompson JB, Weatherhead JG, Koble CS, Allen SH, Schaller LT, Sherrill RG, Yoshinaga T, Kobayashi M, Wakasa-Morimoto C, Miki S, Nakahara K, Noshi T, Sato A, Fujiwara T. The naphthyridinone GSK364735 is a novel, potent human immunodeficiency virus type 1 integrase inhibitor and antiretroviral. Antimicrob Agents Chemother. 2008;52:901–8. [PubMed]Randomized, placebo-controlled, ascending multiple dose study to evaluate the safety, pharmacokinetics, and pharmacodynamics of BMS-707035 in HIV-1 infected subjects [online]. http://www.clinicalTrials.gov Trial identifier: NCT00397566. Pace P, Di Francesco ME, Gardelli C, Harper S, Muraglia E, Nizi E, Orvieto F, Petrocchi A, Poma M, Rowley M, Scarpelli R, Laufer R, Gonzalez Paz O, Monteagudo E, Bonelli F, Hazuda D, Stillmock KA, Summa V. Dihydroxypyrimidine-4-carboxamides as novel potent and selective HIV integrase inhibitors. J Med Chem. 2007;50:2225–39. [PubMed]Gardelli C, Nizi E, Muraglia E, Crescenzi B, Ferrara M, Orvieto F, Pace P, Pescatore G, Poma M, Ferreira Mdel R, Scarpelli R, Homnick CF, Ikemoto N, Alfieri A, Verdirame M, Bonelli F, Paz OG, Taliani M, Montegudo E, Pesci S, Laufer R, Felock P, Stillmock KA, Hazuda D, Rowley M, Summa V. Discovery and synthesis of HIV integrase inhibitors: development of potent and orally bioavailable N-methyl pyrimidones. J Med Chem. 2007;50:4953–75. [PubMed]Di Francesco ME, Pace P, Fiore F, Naimo F, Bonelli F, Rowley M, Summa V. Development of 2- tbutyl- N-methyl pyrimidones as potent inhibitors of HIV integrase. Bioorg Med Chem Lett. 2008;18:2709–13. [PubMed]Wai JS, Kim B, Fisher TE, Zhuang L, Embrey MW, Williams PD, Staas DD, Culberson C, Lyle TA, Vacca JP, Hazuda DJ, Felock PJ, Schleif WA, Gabryelski LJ, Jin L, Chen IW, Ellis JD, Mallai R, Young SD. Dihyhdroxypyridopyrazine-1,6-dione HIV-1 integrase inhibitors. Bioorg Med Chem Lett. 2007;17:5595–9. [PubMed]Muraglia E, Kinzel O, Gardelli C, Crescenzi B, Donghi M, Ferrara M, Nizi E, Orvieto F, Pescatore G, Laufer R, Gonzalez-Paz O, Di Marco A, Fiore F, Monteagudo E, Fonsi M, Felock PJ, Rowley M, Summa V. Design and synthesis of bicyclic pyrimidinones as potent and orally bioavailable HIV-1 integrase inhibitors. J Med Chem. 2008;51:861–74. [PubMed]Jin H, Cai RZ, Schacherer L, Jabri S, Tsiang M, Fardis M, Chen X, Chen JM, Kim CU. Design, synthesis, and SAR studies of novel and highly active tri-cyclic HIV integrase inhibitors. Bioorg Med Chem Lett. 2006;16:3989–92. [PubMed]Fardis M, Jin H, Jabri S, Cai RZ, Mish M, Tsiang M, Kim CU. Effect of substitution on novel tricyclic HIV-1 integrase inhibitors. Bioorg Med Chem Lett. 2006;16:4031–5. [PubMed]Jin H, Wright M, Pastor R, Mish M, Metobo S, Jabri S, Lansdown R, Cai R, Pyun P, Tsiang M, Chen X, Kim CU. Tricyclic HIV integrase inhibitors: potent and orally bioavailable C5-aza analogs. Bioorg Med Chem Lett. 2008;18:1388–91. [PubMed]Dayam R, Neamati N. Active site binding modes of the beta-diketoacids: a multi-active site approach in HIV-1 integrase inhibitor design. Bioorg Med Chem. 2004;12:6371–81. [PubMed]Marinello J, Marchand C, Mott BT, Bain A, Thomas CJ, Pommier Y. Comparison of raltegravir and elvitegravir on HIV-1 integrase catalytic reactions and on a series of drug-resistant integrase mutants. Biochemistry. 2008;47:9345–54. [PubMed]Jones G, Ledford R, Yu F, Miller M, Tsiang M, McColl D. Resistance profile of HIV-1 mutants in vitro selected by the HIV-1 integrase inhibitor, GS-9137 (JTK-303). 14th Conference on Retroviruses and Opportunistic Infections, Los Angeles, CA. 2007. Goodman DD, Hluhanich R, Waters J, Margot NA, Fransen S, Gupta A, Huang W, Parkin N, Borroto-Esoda K, Svarovskaia ES, Miller MD, McColl DJ. Integrase inhibitor resistance (elvitegravir/raltegravir) involves complex interactions among primary and secondary resistance mutations: a novel mutation L68V/I associates with E92Q and increases resistance. XVII International HIV Drug Resistance Workshop, Sitges, Spain. 2008. Summa V, Petrocchi A, Bonelli F, Crescenzi B, Donghi M, Ferrara M, Fiore F, Gardelli C, Gonzalez Paz O, Hazuda DJ, Jones P, Kinzel O, Laufer R, Monteagudo E, Muraglia E, Nizi E, Orvieto F, Pace P, Pescatore G, Scarpelli R, Stillmock K, Witmer MV, Rowley M. Discovery of raltegravir, a potent, selective orally bioavailable HIV-integrase inhibitor for the treatment of HIV-AIDS infection. J Med Chem. 2008;51:5843–55. [PubMed]Fikkert V, Hombrouck A, Van Remoortel B, De Maeyer M, Pannecouque C, De Clercq E, Debyser Z, Witvrouw M. Multiple mutations in human immunodeficiency virus-1 integrase confer resistance to the clinical trial drug S-1360. AIDS. 2004;18:2019–28. [PubMed]Kobayashi M, Nakahara K, Seki T, Miki S, Kawauchi S, Suyama A, Wakasa-Morimoto C, kodama M, Endoh T, Oosugi E, Matushita Y, Murai H, Fujishita T, Yoshinaga T, Garvey E, Foster S, Underwood M, Johns B, Sato A, Fujiwara T. Selection of diverse and clinically relevant integrase inhibitor-resistant human immunodeficiency virus type 1 mutants. Antiviral Res. 2008;80:213–22. [PubMed]Kodama E, Shimura K, Sakagami Y. In vitro antiviral activity and resistance profile of a novel HIV integrase inhibitor JTK-303/GS-9137. 46th Interscience Conference on Antimicrobial Agents and Chemotherapy Sep 27–30, 2006 San Francisco, CA. Nakahara K, Wakasa-Morimoto C, Kobayashi M, Miki S, Noshi T, Seki T, Kanamori-Koyama M, Kawuchi S, Suyama A, Fujishita T, Yoshinaga T, Garvey EP, Johns BA, Foster SA, Underwood MR, Sato A, Fujiwara T. Secondary mutations in viruses resistant to HIV-1 integrase inhibitors that restore viral infectivity and replication kinetics. Antiviral Res. 2009;81:2. Rhee SY, Liu TF, Kiuchi M, Zioni R, Gifford RJ, Holmes SP, Shafer RW. Natural variation of HIV-1 group M integrase: Implications for a new class of antiretroviral inhibitors. Retrovirology. 2008;5:74. [PubMed]
|